S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Laser breakthrough could send stock soaring 2,467% (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
66,000% upside on tiny biotech? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
66,000% upside on tiny biotech? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Laser breakthrough could send stock soaring 2,467% (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
66,000% upside on tiny biotech? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
66,000% upside on tiny biotech? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Laser breakthrough could send stock soaring 2,467% (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
66,000% upside on tiny biotech? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
66,000% upside on tiny biotech? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
S&P 500   4,288.39
DOW   33,433.35
QQQ   361.26
Nvidia Stock, Christmas Comes Early If You’re On the Fence
Laser breakthrough could send stock soaring 2,467% (Ad)
Ride the Waves of Wealth With This Oil Tanker 17% Yield
Here’s Why Cloudflare may be the Ultimate Cloud Stock to Own
66,000% upside on tiny biotech? (Ad)
Peloton and Lululemon, Does the Deal Make Sense?
2 Seasonal Stocks to Warm Up Your Portfolio
66,000% upside on tiny biotech? (Ad)
Fed's Powell gets an earful about inflation and interest rates from small businesses
Sam Bankman-Fried must now convince a jury that the former crypto king was not a crook
NASDAQ:CLRB

Cellectar Biosciences (CLRB) Stock Forecast, Price & News

$2.86
+0.22 (+8.33%)
(As of 10/2/2023 ET)
Compare
Today's Range
$2.70
▼
$3.15
50-Day Range
$1.60
▼
$2.86
52-Week Range
$1.25
▼
$3.70
Volume
565,906 shs
Average Volume
2.00 million shs
Market Capitalization
$27.86 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$7.00
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Cellectar Biosciences MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
144.8% Upside
$7.00 Price Target
Short Interest
Bearish
5.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.71mentions of Cellectar Biosciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($2.23) to ($2.00) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.88 out of 5 stars

Medical Sector

761st out of 975 stocks

Pharmaceutical Preparations Industry

358th out of 444 stocks

See Top Rated MarketRank™ Stocks Here

CLRB stock logo

About Cellectar Biosciences (NASDAQ:CLRB) Stock

Cellectar Biosciences, Inc., a clinical biopharmaceutical company, focuses on the discovery, development, and commercialization of drugs for the treatment of cancer. Its lead phospholipid drug conjugate (PDC) candidate is CLR 131 (iopofosine I-131), which is in Phase 2 clinical study for patients with B-cell malignancies; Phase 2a clinical study for patients with relapsed or refractory (r/r) Waldenstrom's macroglobulinemia cohort, r/r multiple myeloma (MM) cohort, and r/r non-Hodgkin's lymphoma cohort; Phase 1 clinical study for r/r pediatric patients with select solid tumors, lymphomas, and malignant brain tumors; and Phase 1 clinical study for r/r pediatric patients with head and neck cancer. The company also develops CLR 1900, a PDC chemotherapeutic program that is in the preclinical development stage to treat solid tumors. It has collaborative with Orano Med to develop CLR 12120 Series; and LegoChemBio. The company was founded in 2002 and is headquartered in Florham Park, New Jersey.

CLRB Price History

CLRB Stock News Headlines

October 2, 2023 | marketwatch.com
Cellectar Biosciences Shares Rise 10% After Being Granted Four Patents
October 2, 2023 | finance.yahoo.com
Cellectar Biosciences Expands Global Intellectual Property Portfolio with Four Patent Grants
October 3, 2023 | Behind the Markets (Ad)
Jeff Bezos Backs "Drug Smuggler" to Fight Alzheimer's
A small, publicly traded biotech is racing to the discovery of a lifetime: Using a Drug Smuggler to Fight Alzheimer's, Parkinson's and Dementia. This radical treatment is so promising, Biogen, Sanofi and Genentech paid $1 billion to license it. Click here to learn more >>>
September 29, 2023 | americanbankingnews.com
Cellectar Biosciences (NASDAQ:CLRB) Research Coverage Started at StockNews.com
September 18, 2023 | finance.yahoo.com
Cellectar Biosciences Receives European Medicines Agency Priority Medicines (PRIME) Designation for Iopofosine for Waldenstrom’s Macroglobulinemia
September 18, 2023 | benzinga.com
Nano-Cap Medical Technology Watchlist (ORHB, BBLG, CLRB, MOVE)
September 11, 2023 | benzinga.com
Cellectar Biosciences Announces Closing of up to Approximately $103 Million Private Placement Financing
September 5, 2023 | marketwatch.com
Cellectar Biosciences Shares Rise 18% After Private Placement Financing
October 3, 2023 | Behind the Markets (Ad)
Jeff Bezos Backs "Drug Smuggler" to Fight Alzheimer's
A small, publicly traded biotech is racing to the discovery of a lifetime: Using a Drug Smuggler to Fight Alzheimer's, Parkinson's and Dementia. This radical treatment is so promising, Biogen, Sanofi and Genentech paid $1 billion to license it. Click here to learn more >>>
September 5, 2023 | msn.com
Cellectar Biosciences announces up to ~$103M private placement financing
September 5, 2023 | finance.yahoo.com
Cellectar Biosciences Announces up to Approximately $103 Million Private Placement Financing
August 14, 2023 | finanznachrichten.de
Cellectar Biosciences: Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
August 14, 2023 | finance.yahoo.com
Cellectar Reports Financial Results for Second Quarter 2023 and Provides a Corporate Update
June 28, 2023 | finance.yahoo.com
Cellectar Biosciences Highlights Promising Interim Data from Its Ongoing Study of Iopofosine I 131 in Multiple Myeloma in an Oral Presentation at the SNMMI Annual Meeting
June 27, 2023 | finance.yahoo.com
CLRB - Cellectar Biosciences, Inc.
June 12, 2023 | finance.yahoo.com
Cellectar Provides a Research and Development Program Summary
May 6, 2023 | morningstar.com
UPDATE — Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
May 6, 2023 | seekingalpha.com
Cellectar Biosciences GAAP EPS of -$0.76
May 4, 2023 | msn.com
Recap: Cellectar Biosciences Q1 Earnings
May 4, 2023 | finanznachrichten.de
Cellectar Biosciences: Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
May 4, 2023 | finance.yahoo.com
Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
May 4, 2023 | finance.yahoo.com
UPDATE -- Cellectar Reports Financial Results for First Quarter 2023 and Provides a Corporate Update
March 9, 2023 | finanznachrichten.de
Cellectar Biosciences: Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update
March 9, 2023 | finance.yahoo.com
Cellectar Reports Financial Results for Year Ended 2022 and Provides a Corporate Update
March 1, 2023 | markets.businessinsider.com
Maxim Group Keeps Their Buy Rating on Cellectar Biosciences (CLRB)
February 28, 2023 | finance.yahoo.com
Cellectar Biosciences Reports Complete Response in a Relapsed/Refractory CNS Lymphoma Patient
February 15, 2023 | finance.yahoo.com
Cellectar Biosciences Hires Dr. Andrei Shustov as New Senior Vice President, Medical
See More Headlines
Receive CLRB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Cellectar Biosciences and its competitors with MarketBeat's FREE daily newsletter.

CLRB Company Calendar

Last Earnings
8/14/2023
Today
10/02/2023
Next Earnings (Estimated)
11/02/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:CLRB
CUSIP
N/A
CIK
1279704
Web
www.cellectar.com
Phone
(608) 441-8120
Fax
608-441-8121
Employees
15
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$7.00
High Stock Price Forecast
$10.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+144.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($3.32)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-28,600,000.00
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-430.14%
Return on Assets
-204.49%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.87
Quick Ratio
0.87

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.51 per share
Price / Book
1.89

Miscellaneous

Outstanding Shares
9,740,000
Free Float
8,952,000
Market Cap
$27.86 million
Optionable
Not Optionable
Beta
1.14
The Best High-Yield Dividend Stocks for 2023 Cover
The Best High-Yield Dividend Stocks for 2023

Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.

Get This Free Report

Key Executives

  • Mr. James V. Caruso (Age 64)
    Pres, CEO & Director
    Comp: $846.48k
  • Mr. Chad J. Kolean CPA (Age 59)
    CPA, VP, CFO & Sec.
    Comp: $453.22k
  • Mr. Jarrod Longcor (Age 50)
    Chief Operating Officer
    Comp: $625.32k
  • Mr. Darrell Shane Lea (Age 50)
    Chief Commercial Officer
  • Dr. Andrei Shustov M.D. (Age 52)
    Sr. VP of Medical

Key Competitors

View All Competitors

Institutional Ownership

View All Institutional Transactions













CLRB Stock - Frequently Asked Questions

Should I buy or sell Cellectar Biosciences stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Cellectar Biosciences in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CLRB shares.
View CLRB analyst ratings or view top-rated stocks.

What is Cellectar Biosciences' stock price forecast for 2023?

1 analysts have issued 1 year target prices for Cellectar Biosciences' stock. Their CLRB share price forecasts range from $4.00 to $10.00. On average, they anticipate the company's stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 144.8% from the stock's current price.
View analysts price targets for CLRB or view top-rated stocks among Wall Street analysts.

How have CLRB shares performed in 2023?

Cellectar Biosciences' stock was trading at $1.71 on January 1st, 2023. Since then, CLRB shares have increased by 67.3% and is now trading at $2.86.
View the best growth stocks for 2023 here.

Are investors shorting Cellectar Biosciences?

Cellectar Biosciences saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 482,200 shares, an increase of 238.4% from the August 31st total of 142,500 shares. Based on an average daily trading volume, of 620,200 shares, the days-to-cover ratio is currently 0.8 days. Currently, 5.2% of the company's shares are sold short.
View Cellectar Biosciences' Short Interest.

When is Cellectar Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023.
View our CLRB earnings forecast.

How were Cellectar Biosciences' earnings last quarter?

Cellectar Biosciences, Inc. (NASDAQ:CLRB) announced its quarterly earnings data on Monday, August, 14th. The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.69) by $0.04.

When did Cellectar Biosciences' stock split?

Cellectar Biosciences shares reverse split on the morning of Friday, July 22nd 2022. The 1-10 reverse split was announced on Friday, July 22nd 2022. The number of shares owned by shareholders was adjusted after the closing bell on Friday, July 22nd 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

What other stocks do shareholders of Cellectar Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Cellectar Biosciences investors own include Hudbay Minerals (HBM), Zynga (ZNGA), Quantum (QTM), Baytex Energy (BTE), Sherritt International (S), Bombardier (BDRBF), Bombardier, Inc. Class B (BBD.B), Bonavista Energy Co. (BNP.TO) (BNP) and Hudbay Minerals (HBM).

What is Cellectar Biosciences' stock symbol?

Cellectar Biosciences trades on the NASDAQ under the ticker symbol "CLRB."

How do I buy shares of Cellectar Biosciences?

Shares of CLRB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Cellectar Biosciences' stock price today?

One share of CLRB stock can currently be purchased for approximately $2.86.

How much money does Cellectar Biosciences make?

Cellectar Biosciences (NASDAQ:CLRB) has a market capitalization of $27.86 million. The biopharmaceutical company earns $-28,600,000.00 in net income (profit) each year or ($3.32) on an earnings per share basis.

How can I contact Cellectar Biosciences?

Cellectar Biosciences' mailing address is 100 CAMPUS DRIVE, FLORHAM PARK NJ, 07932. The official website for the company is www.cellectar.com. The biopharmaceutical company can be reached via phone at (608) 441-8120, via email at ir@cellectar.com, or via fax at 608-441-8121.

This page (NASDAQ:CLRB) was last updated on 10/3/2023 by MarketBeat.com Staff

My Account -